Medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX) announced on Wednesday that it has launched the BD Intraosseous (IO) Vascular Access System, designed to provide rapid vascular access in critical care situations where intravenous (IV) access may be challenging.
This innovative system allows clinicians to administer fluids and medications by inserting a needle into the bone marrow, providing quick access for both adult and paediatric patients.
The BD IO System uniquely features an integrated passive needle tip safety to reduce needlestick injuries and is the only IO device allowing placement after the extension set attachment. With a rechargeable battery that extends drill life up to 12 times over non-rechargeable options, it also includes a multi-light battery indicator for immediate power status assessment. This system demonstrates a 93–97% success rate for trained users and offers higher success in critical cases where low blood pressure hinders standard IV access.
Now available in the US, the BD IO System enhances safety and effectiveness for emergency care providers, furthering BD's commitment to advancing healthcare solutions globally.
Lundbeck receives FDA Fast Track designation for amlenetug in multiple system atrophy
Moleculin's Phase 3 R/R AML pivotal trial receives first European country recruitment approval
Biohaven secures FDA priority review for troriluzole in spinocerebellar ataxia
Owens & Minor launches ByramConnect digital health platform for diabetes management
Novartis to acquire Anthos Therapeutics in USD925m deal to expand cardiovascular pipeline
bioMérieux secures US FDA clearance for new gastrointestinal diagnostic panel
EssilorLuxottica expands med-tech portfolio with Cellview acquisition
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Hemab Therapeutics reveals interim data from ongoing HMB-001 phase two study
AbbVie's EMBLAVEO receives US FDA approval for complicated intra-abdominal infections
Eton Pharmaceuticals secures US patent for ET-600, protecting formulation through 2044
Lilly's Omvoh shows sustained efficacy in Crohn's disease after two years
Bio-Thera Solutions secures EMA acceptance for BAT2506 biosimilar application
BioArctic reports strong royalty growth from Leqembi sales in Q4 2024